Dongkook Pharmaceutical-Jinwoo Bio Sign Business Agreement to Develop Innovative Products Using Solidified Hyaluronic Acid Technology Platform

From the left, Dongkook Pharmaceutical Research Director Lee Gye-wan, CEO Song Junho, Jinwoo Bio CEO Kwon Dong-geon, Executive Director Jang Young-gi

[Asia Economy Reporter Lee Gwan-joo] Dongkook Pharmaceutical announced on the 25th that it has signed a business agreement with Jinwoo Bio, a hyaluronic acid (HA) specialized company, to develop innovative products using the Solid Hyaluronic Acid Technology Platform (SHTP).

Through this agreement, Dongkook Pharmaceutical plans to develop new aesthetic-related products such as film-type stomatitis treatments, hydro patches and wound dressings with anti-adhesion properties using fiber and nonwoven fabric, skin boosters using threads, and fillers for improving fine wrinkles around the eyes by leveraging Jinwoo Bio’s globally patented SHTP technology and its own product development capabilities. The company aims to enter not only the domestic market but also the global market.

Jinwoo Bio’s SHTP is a core technology that uses hyaluronic acid, a bio-material, and wet processing technology, a polymer processing technique, to produce various forms of solid HA such as high-viscosity films, threads, fibers, wool, and fabric sheets without any chemical reactions, using only pure HA.

Song Junho, CEO of Dongkook Pharmaceutical, said, “Through cooperation with Jinwoo Bio, a specialized HA bio company, we will develop new products applying Dongkook Pharmaceutical’s HA filler products and SHTP technology to become a total healthcare company in the beauty and anti-aging fields.”

Kwon Dong-geon, CEO of Jinwoo Bio, said, “We are pleased that the value of SHTP, the world’s first established technology by Jinwoo Bio, has been recognized by Dongkook Pharmaceutical. We expect a high synergy effect in product development for entering not only the domestic but also the global market through research cooperation with Dongkook Pharmaceutical, an innovative pharmaceutical company with excellent capabilities.”